<?xml version="1.0" encoding="UTF-8"?>
<?xml-model href="http://docbook.org/xml/5.1/rng/docbook.rng" schematypens="http://relaxng.org/ns/structure/1.0"?>
<?xml-model href="http://docbook.org/xml/5.1/rng/docbook.rng" type="application/xml" schematypens="http://purl.oclc.org/dsdl/schematron"?>
<book xmlns="http://docbook.org/ns/docbook"
    xmlns:xlink="http://www.w3.org/1999/xlink" version="5.1">
    <info>
        <title>Clinical Decision Support (CDS) Content and Health Level 7 (HL7)-Compliant Knowledge
            Artifacts (KNARTs)</title>
        <subtitle>Cardiology: Inpatient Heparin Anticoagulation Protocol Clinical Content White
            Paper </subtitle>
        <copyright>
            <year>2018</year>
            <holder>B3 Group, Inc.</holder>
        </copyright>
        <legalnotice>
            <title>B3 Group, Inc.</title>
            <para>NOTICE OF GOVERNMENT COPYRIGHT LICENSE AND UNLIMITED RIGHTS LICENSE</para>
            <para>Licensed under the Apache License, Version 2.0 (the "License"); you may not use
                this file except in compliance with the License.</para>
            <para>You may obtain a copy of the License at <link
                    xlink:href="http://www.apache.org/licenses/LICENSE-2.0"
                    >http://www.apache.org/licenses/LICENSE-2.0</link>
            </para>
            <para>Unless required by applicable law or agreed to in writing, software distributed
                under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR
                CONDITIONS OF ANY KIND, either express or implied. See the License for the specific
                language governing permissions and limitations under the License.</para>
            <para>Portions of this content are derivative works from content produced by Cognitive
                Medical Systems, Inc. licensed under the Apache License, Version 2.0.</para>
            <para>Additional portions of this content are derivative works from content contributed
                by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike
                4.0.</para>
            <para>Contributions from 2013-2018 were performed either by US Government employees, or
                under US Veterans Health Administration contracts.</para>
            <para>US Veterans Health Administration contributions by government employees are work
                of the U.S. Government and are not subject to copyright protection in the United
                States. Portions contributed by government employees are USGovWork (17USC §105). Not
                subject to copyright.</para>
            <para>See: <link xlink:href="https://www.usa.gov/government-works"
                    >https://www.usa.gov/government-works</link>
            </para>
            <para>Contribution by contractors to the US Veterans Health Administration during this
                period are contractually contributed under the Apache License, Version 2.0 and US
                Government sponsorship is acknowledged under Contract VA118-16-D-1008, Task Order
                VA11817F10080007.</para>
        </legalnotice>
        <copyright>
            <year>2018</year>
            <holder>Cognitive Medical Systems, Inc.</holder>
        </copyright>
        <legalnotice>
            <title>Cognitive Medical Systems, Inc.</title>
            <para>Licensed under the Apache License, Version 2.0 (the "License"); you may not use
                this file except in compliance with the License.</para>
            <para>You may obtain a copy of the License at <link
                    xlink:href="http://www.apache.org/licenses/LICENSE-2.0"
                    >http://www.apache.org/licenses/LICENSE-2.0</link>
            </para>
            <para>Unless required by applicable law or agreed to in writing, software distributed
                under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR
                CONDITIONS OF ANY KIND, either express or implied. See the License for the specific
                language governing permissions and limitations under the License.</para>
            <para>This and related content produced by Cognitive Medical Systems, Inc. licensed
                under the Apache License, Version 2.0 is available at: <link
                    xlink:href="https://bitbucket.org/cogmedsys/hl7-kas-examples"
                    >https://bitbucket.org/cogmedsys/hl7-kas-examples</link>
            </para>
            <para>Additional portions of this content are derivative works from content contributed
                by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike
                4.0. <link xlink:href="https://bitbucket.org/cogmedsys/kas-source-material"
                    >https://bitbucket.org/cogmedsys/kas-source-material</link>
            </para>
            <para>Contributions from 2013-2018 were performed either by US Government employees, or
                under US Veterans Health Administration contracts.</para>
            <para>US Veterans Health Administration contributions by government employees are work
                of the U.S. Government and are not subject to copyright protection in the United
                States. Portions contributed by government employees are USGovWork (17USC §105). Not
                subject to copyright. See: <link xlink:href="https://www.usa.gov/government-works"
                    >https://www.usa.gov/government-works</link>
            </para>
            <para>Contribution by contractors to the US Veterans Health Administration during this
                period are contractually contributed under the Apache License, Version 2.0 and US
                Government sponsorship is acknowledged under Contract VA118-16-D-1008-0007.</para>
        </legalnotice>
        <authorgroup>
            <author>
                <personname>Department of Veterans Affairs (VA)</personname>
            </author>
            <author>
                <orgname><inlinemediaobject>
                        <imageobject>
                            <imagedata fileref="ccwp_resource/VASealColor.jpg"/>
                        </imageobject>
                    </inlinemediaobject></orgname>
            </author>
            <author>
                <orgname>Knowledge Based Systems (KBS)</orgname>
            </author>
            <author>
                <orgname>Office of Informatics and Information Governance (OIIG)</orgname>
            </author>
            <author>
                <orgname>Clinical Decision Support (CDS)</orgname>
            </author>
        </authorgroup>
        <abstract>
            <info>
                <title>Contract: VA118-16-D-1008, Task Order (TO): VA-118-16-F-1008-0007</title>
            </info>
            <para>
                <table colsep="1" frame="all" rowsep="1">
                    <title>Relevant KNART Information: Cardiology: Inpatient Heparin Anticoagulation
                        Protocol</title>
                    <tgroup align="left" cols="2">
                        <thead>
                            <row>
                                <entry>Gastroenterology KNART</entry>
                                <entry>Associated CLIN</entry>
                            </row>
                        </thead>
                        <tbody>
                            <row>
                                <entry>Inpatient Heparin Anticoagulation Protocol – Event Condition
                                    Action (ECA) Rule</entry>
                                <entry>CLIN0007CA</entry>
                            </row>
                            <row>
                                <entry>Inpatient Heparin Anticoagulation Protocol – Order Set </entry>
                                <entry>CLIN0008DA</entry>
                            </row>
                        </tbody>
                    </tgroup>
                </table>
            </para>
        </abstract>
        <pubdate>June 2018</pubdate>
        <volumenum>Version 1.0</volumenum>
    </info>
    <preface xml:id="d0e98">
        <title>VA Subject Matter Expert (SME) Panel</title>
        <para>
            <table frame="all">
                <title>VA Subject Matter Expert (SME) Panel</title>
                <tgroup cols="3" align="left" colsep="1" rowsep="1">
                    <colspec colname="c1" colnum="1" colwidth="1*"/>
                    <colspec colname="c2" colnum="2" colwidth="2.29*"/>
                    <colspec colname="c3" colnum="3" colwidth="1.71*"/>
                    <thead>
                        <row>
                            <entry>Name</entry>
                            <entry>Title</entry>
                            <entry>Project Role</entry>
                        </row>
                    </thead>
                    <tbody>
                        <row>
                            <entry><para>Bruce Bray, MD</para></entry>
                            <entry><para>Professor, Cardiovascular Medicine University of Utah
                                    School of Medicine Staff Cardiologist, Salt Lake City (SLC) VA
                                    Medical Center (VAMC)</para></entry>
                            <entry><para>SME, Primary</para></entry>
                        </row>
                        <row>
                            <entry><para>Scott Wall, MD</para></entry>
                            <entry><para>Assistant Professor, Cardiovascular Medicine University of
                                    Utah School of Medicine Staff Cardiologist, Electrophysiology
                                    Salt Lake City VAMC</para></entry>
                            <entry><para>SME, Secondary</para></entry>
                        </row>
                        <row>
                            <entry><para>Aiden Abidov, MD, PhD</para></entry>
                            <entry><para>Professor of Medicine Wayne State University Section Chief,
                                    Cardiology John Dingell VA Medical Center</para></entry>
                            <entry><para>SME</para></entry>
                        </row>
                        <row>
                            <entry><para>Claibe Yarbrough, MD</para></entry>
                            <entry><para>National Program Director North Texas VHCS
                                    Pulmonary/Critical Care/Sleep Medicine Dallas, TX</para></entry>
                            <entry><para>SME</para></entry>
                        </row>
                        <row>
                            <entry><para>Benjamin Brooke, MD</para></entry>
                            <entry><para>Attending Salt Lake City VAMC Surgery Services Salt Lake
                                    City, UT</para></entry>
                            <entry><para>SME</para></entry>
                        </row>
                    </tbody>
                </tgroup>
            </table></para>
    </preface>
    <preface xml:id="d0e147">
        <title>Introduction</title>
        <para>The VA is committed to improving the ability of clinicians to provide care for
            patients while increasing quality, safety, and efficiency. Recognizing the importance of
            standardizing clinical knowledge in support of this goal, VA is implementing the Health
            Level 7 (HL7) Knowledge Artifact Specification for a wide range of VA clinical use
            cases. Knowledge Artifacts, referred to as (KNARTs), enable the structuring and encoding
            of clinical knowledge so the knowledge can be integrated with electronic health records
            to enable clinical decision support.</para>
        <para>The purpose of this Clinical Content White Paper (CCWP) is to capture the clinical
            context and intent of KNART use cases in sufficient detail to provide the KNART
            authoring team with the clinical source material to construct the corresponding
            knowledge artifacts using the HL7 Knowledge Artifact Specification. This paper has been
            developed using material from a variety of sources: VA artifacts, clinical practice
            guidelines, evidence in the body of medical literature, and clinical expertise. After
            reviewing these sources, the material has been synthesized and harmonized under the
            guidance of VA subject matter experts to reflect clinical intent for this use
            case.</para>
        <para>Unless otherwise noted, items within this white paper (e.g., documentation template
            fields, orderable items, etc.) are chosen to reflect the clinical intent at the time of
            creation. To provide an exhaustive list of all possible items and their variations is
            beyond the scope of this work.</para>
    </preface>
    <preface xml:id="d0e156">
        <title>Conventions Used</title>
        <para> Conventions used within the knowledge artifact descriptions include: </para>
        <para> &lt;obtain&gt;: Indicates a prompt to obtain the information listed </para>
        <itemizedlist>
            <listitem>
                <para> If possible, the requested information should be obtained from the underlying
                    system(s). Otherwise, prompting the user for information may be required </para>
            </listitem>
            <listitem>
                <para>The technical and clinical notes associated with a section should be consulted
                    for specific constraints on the information (e.g., time-frame, patient
                    interview, etc.).</para>
            </listitem>
            <listitem>
                <para> Default Values: Unless otherwise noted, &lt;obtain&gt; indicates to obtain
                    the most recent observation. It is recognized that this default time-frame value
                    may be altered by future implementations </para>
            </listitem>
        </itemizedlist>
        <para> [...]: Square brackets enclose explanatory text that indicates some action on the
            part of the clinical user, or general guidance to the clinical or technical teams.
            Examples include, but are not limited to: </para>
        <blockquote>
            <para> [Begin ...], [End ...]: Indicates the start and end of specific areas to clearly
                delineate them for technical purposes. </para>
            <para> [Activate ...]: Initiates another knowledge artifact or knowledge artifact
                section. </para>
            <para> [Section Prompt: ...]: If this section is applicable, then the following prompt
                should be displayed to the user. </para>
            <para> [Section Selection Behavior: ...]: Indicates technical constraints or
                considerations for the selection of items within the section. </para>
            <para> [Attach: ...]: Indicates that the specified item should be attached to the
                documentation template if available. </para>
            <para> [Link: ...]: Indicates that rather than attaching an item, a link should be
                included in the documentation template. </para>
            <para> [Clinical Comment: ...]: Indicates clinical rationale or guidance. </para>
            <para> [Technical Note: ...]: Indicates technical considerations or notes. </para>
            <para> [If ...]: Indicates the beginning of a conditional section. </para>
            <para> [Else, ...]: Indicates the beginning of the alternative branch of a conditional
                section. </para>
            <para> [End if ...]: Indicates the end of a conditional section. </para>
        </blockquote>
        <para> &#9744;: Indicates items that should be selected based upon the section selection
            behavior. </para>

    </preface>
    <chapter xml:id="d0e212">
        <title>Inpatient Heparin Anticoagulation Protocol</title>
        <section xml:id="d0e215">
            <title>Clinical Context</title>
            <para>[Begin Clinical Context.]</para>
            <para>This set of KNARTs is intended to facilitate identification of inpatients
                requiring therapeutic anticoagulation management and initiate actions for
                anticoagulation management in conditions for which unfractionated intravenous (IV)
                heparin is indicated. The primary focus is on therapeutic anticoagulation with
                unfractionated intravenous heparin for patients with Venous thromboembolism (VTE)
                disease in acute care, with branches within the order set for subpopulations of
                patients. Within each branch, as appropriate, orders will include nursing orders and
                protocols, unfractionated intravenous heparin protocol (including dose and timing
                adjustments), and patient body weight and other measures needed to guide
                therapy.</para>
            <para>
                <table>
                    <title>Clinical Context Domains</title>
                    <tgroup cols="2">
                        <tbody>
                            <row>
                                <entry>Target User</entry>
                                <entry>
                                    <para>Hospitalists, Residents and other ordering providers
                                        involved in managing the patient cohort, Nursing</para>
                                </entry>
                            </row>
                            <row>
                                <entry>Patient</entry>
                                <entry>
                                    <para>Adult inpatients requiring therapeutic anticoagulation
                                        management</para>
                                </entry>
                            </row>
                            <row>
                                <entry>Priority</entry>
                                <entry>
                                    <para>Routine</para>
                                </entry>
                            </row>
                            <row>
                                <entry>Specialty</entry>
                                <entry>
                                    <para>Medical or Surgical service</para>
                                </entry>
                            </row>
                            <row>
                                <entry>Location</entry>
                                <entry>
                                    <para>Inpatient</para>
                                </entry>
                            </row>
                        </tbody>
                    </tgroup>
                </table></para>
            <para xml:id="d0e250">[End Clinical Context.]</para>
        </section>
        <section>
            <title>Knowledge Artifacts</title>
            <para>[Begin Knowledge Artifacts.]</para>
            <para>This section describes the CDS knowledge artifacts that are part of the Cardiology
                Inpatient Heparin Anticoagulation Protocol group, and include:</para>
            <itemizedlist>
                <listitem xml:id="d0e256">
                    <para>Order Set</para>
                    <itemizedlist mark="none">
                        <listitem xml:id="d0e260">
                            <para>Orderable items associated with the management of inpatients
                                requiring therapeutic anticoagulation </para>
                        </listitem>
                        <listitem xml:id="d0e263">
                            <para>Includes logic for appropriate display of the order set</para>
                        </listitem>
                    </itemizedlist>
                </listitem>
                <listitem xml:id="d0e266">
                    <para>Event-Condition-Action (ECA) Rule </para>
                    <itemizedlist mark="none">
                        <listitem>
                            <para>Rule logic for sending notifications, activating order sets, and
                                providing guidelines to clinicians</para>
                        </listitem>
                        <listitem xml:id="d0e270">
                            <para>Actions may include sending notification to providers relevant to
                                therapeutic anticoagulation management, activating order sets, or
                                ensuring that clinicians have access to the current guidelines for
                                Inpatient Heparin Anticoagulation </para>
                        </listitem>
                    </itemizedlist>
                </listitem>
            </itemizedlist>
            <para>[End Knowledge Artifacts.]</para>
        </section>
    </chapter>
    <chapter xml:id="d0e276">
        <title>Event Condition Action (ECA) Rule</title>
        <section xml:id="d0e279">
            <title>Knowledge Narrative</title>
            <para>[Begin Knowledge Narrative.]</para>
            <para>Venous thromboembolism (VTE) is a common medical problem that results in
                substantial morbidity and mortality. Despite its prevalence, clinicians often fail
                to appreciate the risks for VTE and often fail to recognize its signs and symptoms;
                this has led the National Academy of Sciences to cite it as a frequent cause of
                diagnostic error (National Academies of Sciences 2015). The problem of diagnostic
                error in VTE is compounded by therapeutic error—largely involving anticoagulants,
                which are perennially among the medications most often associated with adverse drug
                events (Shehab 2016). Remediating the problem requires the adoption of
                evidence-based guidelines, notably those of the American College of Chest Physicians
                (Kearon 2012), across an entire health system. Rendering such guidelines operational
                requires meticulous curation of an array of granular elements across the full
                spectrum of clinical conditions (e.g., medical versus surgical patients, orthopedic
                versus nonorthopedic surgical patients, intracranial/spinal surgery, etc.) and the
                management of numerous comorbidities and factors that have potential to complicate
                care and predispose patients to iatrogenic bleeding (hemorrhagic diathesis, renal
                failure, etc.). Deploying such decision support within the VA system offers the
                potential for improvement in patient care, and avoidance of preventable morbidity
                and mortality.</para>
            <para>[End Knowledge Narrative.]</para>
        </section>
        <section xml:id="d0e284">
            <title>ECA Rules: Event Condition Action</title>
            <para>Inpatient Heparin Anticoagulation Protocol</para>
            <para>[Begin ECA Rules: Event Condition Action.]</para>
            <section xml:id="d0e289">
                <title>Acute Deep vein thrombosis (DVT) of Leg Treated with Vitamin K
                    Antagonist</title>
                <para>[Begin Acute Deep vein thrombosis (DVT) of Leg Treated with Vitamin K
                    Antagonist.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute deep venous
                    thrombosis of the leg. The patient is receiving vitamin K antagonist therapy.
                    The patient is not receiving low-molecular-weight heparin. The patient is not
                    receiving fondaparinux. The patient is not receiving intravenous unfractionated
                    heparin. The patient is not receiving subcutaneous unfractionated heparin. The
                    patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate Inpatient Heparin Anticoagulation Order Set KNART.</para>
                <para>[End Acute Deep vein thrombosis (DVT) of Leg Treated with Vitamin K
                    Antagonist.]</para>
            </section>
            <section xml:id="d0e307">
                <title>High Clinical Suspicion of Acute Venous thromboembolism (VTE)</title>
                <para>[Begin High Clinical Suspicion of Acute Venous thromboembolism (VTE).]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has a highly suspected acute
                    venous thromboembolism. Diagnostic test results are not available. The patient
                    is not receiving low-molecular-weight heparin. The patient is not receiving
                    fondaparinux. The patient is not receiving intravenous unfractionated heparin.
                    The patient is not receiving subcutaneous unfractionated heparin. The patient is
                    not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End High Clinical Suspicion of Acute Venous thromboembolism (VTE).]</para>
            </section>
            <section xml:id="d0e325">
                <title>Intermediate Clinical Suspicion of Acute Venous thromboembolism (VTE) and
                    Results of Diagnostic Tests Expected to Be Delayed &gt; 4 Hours</title>
                <para>[Begin Intermediate Clinical Suspicion of Acute Venous thromboembolism (VTE)
                    and Results of Diagnostic Tests Expected to Be Delayed &gt; 4 Hours.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an intermediately suspected
                    acute venous thromboembolism. Diagnostic test results are not available.
                    Diagnostic test results are not expected to be received within the next 4 hours.
                    The patient is not receiving low-molecular-weight heparin. The patient is not
                    receiving fondaparinux. The patient is not receiving intravenous unfractionated
                    heparin. The patient is not receiving subcutaneous unfractionated heparin. The
                    patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Intermediate Clinical Suspicion of Acute Venous thromboembolism (VTE) and
                    Results of Diagnostic Tests Expected to Be Delayed &gt; 4 Hours.]</para>
            </section>
            <section xml:id="d0e343">
                <title>Acute Isolated Distal Deep vein thrombosis (DVT) of Leg and Severe Symptoms
                    or Risk Factors for Extension</title>
                <para>[Begin Acute Isolated Distal Deep vein thrombosis (DVT) of Leg and Severe
                    Symptoms or Risk Factors for Extension.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute isolated distal
                    deep venous thrombosis of the leg. The patient has severe symptoms related to
                    the deep venous thrombosis OR the patient has risk factors for extension. The
                    patient is not receiving anticoagulation therapy. The patient is not
                    pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para xml:id="d0e361">[End Acute Isolated Distal Deep vein thrombosis (DVT) of Leg
                    and Severe Symptoms or Risk Factors for Extension.]</para>
            </section>
            <section>
                <title>Acute Isolated Distal Deep vein thrombosis (DVT) of Leg if Thrombus Extends
                    within Distal System or into Proximal Veins</title>
                <para>[Begin Acute Isolated Distal Deep vein thrombosis (DVT) of Leg if Thrombus
                    Extends within Distal System or into Proximal Veins.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute isolated distal
                    deep venous thrombosis of the leg. The thrombus extends within the distal veins
                    OR the thrombus extends into the proximal veins. The patient is not receiving
                    anticoagulation therapy. The patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Acute Isolated Distal Deep vein thrombosis (DVT) of Leg if Thrombus
                    Extends within Distal System or into Proximal Veins.]</para>
            </section>
            <section xml:id="d0e379">
                <title>Acute Deep vein thrombosis (DVT) of Leg with Thrombectomy</title>
                <para>[Begin Acute Deep vein thrombosis (DVT) of Leg with Thrombectomy.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute deep venous
                    thrombosis of the leg. The patient is undergoing thrombectomy. The patient is
                    not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Notify the provider that the patient should be considered for the
                    same intensity and duration of anticoagulation therapy irrespective of the
                    thrombosis removal. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Acute Deep vein thrombosis (DVT) of Leg with Thrombectomy.]</para>
            </section>
            <section xml:id="d0e397">
                <title>Acute Proximal Deep vein thrombosis (DVT) of Leg and Inferior vena cava (IVC)
                    Filter If Risk of Bleeding Resolves</title>
                <para>[Begin Acute Proximal Deep vein thrombosis (DVT) of Leg and Inferior vena cava
                    (IVC) Filter If Risk of Bleeding Resolves.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute proximal deep
                    venous thrombosis of the leg. The patient has received an inferior vena cava
                    (IVC) filter. The patient does not have a current active risk of bleeding. The
                    patient is not receiving anticoagulation therapy. The patient is not
                    pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Acute Proximal Deep vein thrombosis (DVT) of Leg and Inferior vena cava
                    (IVC) Filter If Risk of Bleeding Resolves.]</para>
            </section>
            <section xml:id="d0e415">
                <title xml:lang="en-US"><phrase xml:lang="en">Acute </phrase>Pulmonary Embolism (PE) </title>
                <para>[Begin Acute Pulmonary Embolism (PE).]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute pulmonary
                    embolism. The patient is not receiving low-molecular-weight heparin. The patient
                    is not receiving fondaparinux. The patient is not receiving intravenous
                    unfractionated heparin. The patient is not receiving subcutaneous unfractionated
                    heparin. The patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Acute Pulmonary Embolism (PE).]</para>
            </section>
            <section xml:id="d0e433">
                <title>High Clinical Suspicion of Acute Pulmonary Embolism (PE)</title>
                <para>[Begin High Clinical Suspicion of Acute Pulmonary Embolism (PE).]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has a highly suspected acute
                    pulmonary embolism. Diagnostic test results are not available. The patient is
                    not receiving low-molecular-weight heparin. The patient is not receiving
                    fondaparinux. The patient is not receiving intravenous unfractionated heparin.
                    The patient is not receiving subcutaneous unfractionated heparin. The patient is
                    not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End High Clinical Suspicion of Acute Pulmonary Embolism (PE).]</para>
            </section>
            <section xml:id="d0e451">
                <title>Intermediate Clinical Suspicion of Acute Pulmonary Embolism (PE) if Results
                    of Diagnostic Tests Expected to Be Delayed &gt; 4 Hours</title>
                <para>[Begin Intermediate Clinical Suspicion of Acute Pulmonary Embolism (PE) if
                    Results of Diagnostic Tests Expected to Be Delayed &gt; 4 Hours.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an intermediately suspected
                    acute pulmonary embolism. Diagnostic test results are not available. Diagnostic
                    test results are not expected to be received within the next 4 hours. The
                    patient is not receiving low-molecular-weight heparin. The patient is not
                    receiving fondaparinux. The patient is not receiving intravenous unfractionated
                    heparin. The patient is not receiving subcutaneous unfractionated heparin. The
                    patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Intermediate Clinical Suspicion of Acute Pulmonary Embolism (PE) if
                    Results of Diagnostic Tests Expected to Be Delayed &gt; 4 Hours.]</para>
            </section>
            <section xml:id="d0e469">
                <title>Acute Pulmonary Embolism (PE) and Inferior vena cava (IVC) Filter if Risk of
                    Bleeding Resolves</title>
                <para>[Begin Acute Pulmonary Embolism (PE) and Inferior vena cava (IVC) Filter if
                    Risk of Bleeding Resolves.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute pulmonary
                    embolism. The patient has received an inferior vena cava (IVC) filter. The
                    patient does not have a current active risk of bleeding. The patient is not
                    receiving anticoagulation therapy. The patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Acute Pulmonary Embolism (PE) and Inferior vena cava (IVC) Filter if Risk
                    of Bleeding Resolves.]</para>
            </section>
            <section xml:id="d0e487">
                <title>Asymptomatic Pulmonary Embolism (PE)</title>
                <para>[Begin Asymptomatic Pulmonary Embolism (PE).]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an asymptomatic pulmonary
                    embolism. The patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Notify the provider that the patient should be considered for the
                    same anticoagulation therapy irrespective of the absence of symptoms related to
                    the pulmonary embolism. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Asymptomatic Pulmonary Embolism (PE).]</para>
            </section>
            <section xml:id="d0e505">
                <title>Acute Upper-Extremity Deep vein thrombosis (DVT) That Involves Axillary or
                    More Proximal Veins</title>
                <para>[Begin Acute Upper-Extremity Deep vein thrombosis (DVT) That Involves Axillary
                    or More Proximal Veins.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute upper extremity
                    deep venous thrombosis involving the axillary veins OR the patient has an acute
                    upper extremity deep venous thrombosis involving more proximal veins. The
                    patient is not receiving low-molecular-weight heparin. The patient is not
                    receiving fondaparinux. The patient is not receiving intravenous unfractionated
                    heparin. The patient is not receiving subcutaneous unfractionated heparin. The
                    patient is not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Acute Upper-Extremity Deep vein thrombosis (DVT) That Involves Axillary
                    or More Proximal Veins.]</para>
            </section>
            <section xml:id="d0e523">
                <title>Acute Upper-Extremity Deep vein thrombosis (DVT) with Thrombolysis</title>
                <para>[Begin Acute Upper-Extremity Deep vein thrombosis (DVT) with
                    Thrombolysis.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has an acute upper extremity
                    deep venous thrombosis. The patient is undergoing thrombolysis. The patient is
                    not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Notify the provider that the patient should be considered for the
                    same intensity and duration of anticoagulation therapy irrespective of the
                    thrombolysis. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Acute Upper-Extremity Deep vein thrombosis (DVT) with
                    Thrombolysis.]</para>
            </section>
            <section xml:id="d0e541">
                <title>Symptomatic Splanchnic Vein Thrombosis</title>
                <para>[Begin Symptomatic Splanchnic Vein Thrombosis.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has symptomatic splanchnic vein
                    thrombosis (defined as portal, mesenteric, splenic, or a combination of these).
                    The patient is not receiving anticoagulation therapy. The patient is not
                    pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Symptomatic Splanchnic Vein Thrombosis.]</para>
            </section>
            <section xml:id="d0e559">
                <title>Symptomatic Hepatic Vein Thrombosis</title>
                <para>[Begin Symptomatic Hepatic Vein Thrombosis.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient has symptomatic hepatic vein
                    thrombosis. The patient is not receiving anticoagulation therapy. The patient is
                    not pregnant.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred. Generate the Inpatient Heparin Anticoagulation Order Set
                    KNART.</para>
                <para>[End Symptomatic Hepatic Vein Thrombosis.]</para>
            </section>
            <section xml:id="d0e577">
                <title>Perioperative Anticoagulation with Mechanical Heart Valve, Atrial
                    Fibrillation, or Venous thromboembolism (VTE) at High Risk for Additional
                    Thromboembolism</title>
                <para>[Begin Perioperative Anticoagulation with Mechanical Heart Valve, Atrial
                    Fibrillation, or Venous thromboembolism (VTE) at High Risk for Additional
                    Thromboembolism.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient is undergoing elective surgery.
                    The patient is receiving vitamin K antagonist therapy. The patient has a
                    mechanical heart valve OR the patient has atrial fibrillation OR the patient has
                    a venous thromboembolism. The patient has a high risk for thromboembolism. The
                    patient is not receiving bridging anticoagulation therapy.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient should be
                    managed according to the American College of Chest Physicians perioperative
                    anticoagulation management guidelines and include a link to the guidelines
                        (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/</link>), (Douketis,
                    2012, section 2.4).</para>
                <para>[Clinical Comment: “Bridging anticoagulation therapy” that is referred to in
                    the Conditions statement for this rule refers to “the administration of a
                    short-acting anticoagulant, consisting of subcutaneous (SC) low-molecular-weight
                    heparin (LMWH) or IV unfractionated heparin (UFH), for an ~10- to 12-day period
                    during interruption of VKA therapy when the international normalized ratio (INR)
                    is not within a therapeutic range” (Douketis, 2012, section 2.4).]</para>
                <para>[Clinical Comment: The link to the guidelines noted in the Action statement of
                    this ECA Rule is the Douketis 2012 article “Perioperative Management of
                    Antithrombotic Therapy”, and is the article that the URL in the Action statement
                    links to. Note that a large majority of individuals who have a mechanical heart
                    valve, or atrial fibrillation, or a current VTE would also be on current
                    anticoagulation therapy such as a vitamin K antagonist (for example, coumadin).
                    The Douketis article contains detailed discussion and recommendations for
                    managing these patients when they require surgery. For example, for this group
                    of patients who also are considered high risk for thromboembolism, the Douketis
                    article recommends discontinuing vitamin K antagonist treatment and instituting
                    bridging anticoagulation therapy, and gives specific guidelines regarding the
                    choice of timing for implementing each of these actions.]</para>
                <para>[End Perioperative Anticoagulation with Mechanical Heart Valve, Atrial
                    Fibrillation, or Venous thromboembolism (VTE) at High Risk for Additional
                    Thromboembolism.]</para>
            </section>
            <section xml:id="d0e595">
                <title>Perioperative Anticoagulation with Unfractionated heparin (UFH) - Timing of
                    Pre-surgical Stopping of UFH</title>
                <para>[Begin Perioperative Anticoagulation with Unfractionated heparin (UFH) -
                    Timing of Pre-surgical Stopping of UFH.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient is undergoing elective surgery.
                    The patient is receiving bridging anticoagulation with a therapeutic dose of
                    intravenous unfractionated heparin.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient should be
                    managed according to the American College of Chest Physicians perioperative
                    anticoagulation management guidelines and include a link to the guidelines
                        (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/</link> ), (Douketis,
                    2012, section 4.2).</para>
                <para>[End Perioperative Anticoagulation with Unfractionated heparin (UFH) - Timing
                    of Pre-surgical Stopping of UFH.]</para>
            </section>
            <section xml:id="d0e613">
                <title>Pregnancy with Antiphospholipid Antibodies (APLA) Syndrome</title>
                <para>[Begin Pregnancy with Antiphospholipid Antibodies (APLA) Syndrome.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient is pregnant. The patient meets
                    laboratory criteria for antiphospholipid antibody (APLA) syndrome. The patient
                    has a history of &gt;= 3 pregnancy losses.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient should be
                    managed according to the American College of Chest Physicians pregnancy
                    anticoagulation guidelines and include a link to the guidelines (<link
                        xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/</link> ), (Bates,
                    2012, abstract).</para>
                <para>[End Pregnancy with Antiphospholipid Antibodies (APLA) Syndrome.]</para>
            </section>
            <section xml:id="d0e631">
                <title>Pregnancy with Mechanical Heart Valve</title>
                <para>[Begin Pregnancy with Mechanical Heart Valve.]</para>
                <para><bridgehead>Event</bridgehead>The patient is admitted as an inpatient.</para>
                <para><bridgehead>Conditions</bridgehead>The patient is pregnant. The patient has a
                    mechanical heart valve.</para>
                <para><bridgehead>Actions</bridgehead>Notify the provider that the patient should be
                    managed according to the American College of Chest Physicians pregnancy
                    anticoagulation guidelines and include a link to the guidelines (<link
                        xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/</link> ), (Bates,
                    2012, section 12/1/1).</para>
                <para>[End Pregnancy with Mechanical Heart Valve.]</para>
                <para>[End ECA Rules: Event Condition Action.]</para>
            </section>
        </section>
    </chapter>
    <chapter xml:id="d0e649">
        <title>Order Set</title>
        <para>[Begin Order Set.]</para>
        <section xml:id="d0e652">
            <title>Knowledge Narrative</title>
            <para>[Begin Knowledge Narrative.]</para>
            <para>[See Clinical Context in Chapter 1.]</para>
            <para>[End Knowledge Narrative.]</para>
        </section>
        <section xml:id="d0e657">
            <title>Medications</title>
            <para>[Begin Medications.]</para>
            <para>[Technical Note: This section should be available for all patients for whom the
                ECA rule Inpatient Heparin Anticoagulation Protocol is triggered.]</para>
            <section>
                <title>Acute DVT of Leg Treated with Vitamin K Antagonist </title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment:</para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>fondaparinux, </para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).]</para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para> [Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e672">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56–68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e678">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68–82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e684">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e690">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e693">
                        <para>☐ Enoxaparin 1 mg/kg subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e696">
                        <para>☐ Enoxaparin 1.5 mg/kg subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt; 50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e702">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50-100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e708">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt; 100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e714">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e717">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para> [Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para xml:id="d0e723">☐ Heparin 80 U/kg body weight intravenous solution 1 time
                    bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <para xml:id="d0e726">If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase
                    heparin infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin
                    infusion rate change. </para>
                <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin infusion
                    rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion rate change. </para>
                <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current and
                    the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT lab
                    with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and draw
                    aPTT lab 6 hours after heparin infusion rate change. </para>
                <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                    heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                    infusion rate change.</para>
            </section>
            <section>
                <title>High Clinical Suspicion of Acute VTE</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>fondaparinux, </para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).]</para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt;= 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e739">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56-68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e745">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e751">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e757">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e760">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e763">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt;50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e769">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50–100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e775">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt; 100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e781">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e784">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para xml:id="d0e790"> ☐ Heparin 80 U/kg body weight solution intravenous 1 time
                    bolus now</para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Intermediate Clinical Suspicion of Acute VTE and Results of Diagnostic Tests
                    Expect to Be Delayed &gt; 4 Hours</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>fondaparinux, </para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).]</para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt;= 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e806">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56-68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e812">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e818">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e824">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e827">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e830">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt; 50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e836">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50–100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e842">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e848">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e851">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para xml:id="d0e860">[Technical Note: The following orders are for use in
                    management of IV heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Isolated Distal DVT of Leg and Severe Symptoms or Risk Factors for
                    Extension</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e873">
                        <para>☐ Dalteparin 10000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e879">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e885">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e891">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e894">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e897">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours </para>
                    </listitem>
                    <listitem xml:id="d0e900">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Isolated Distal DVT of Leg if Thrombus Extends within Distal System or
                    into Proximal Veins</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt;56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e922">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e928">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e934">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e940">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e943">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e946">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                    <listitem xml:id="d0e949">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Deep Vein Thrombosis of Leg with Thrombosis Removal</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The provider should be advised that the patient should be
                    considered for the same intensity and duration of anticoagulation therapy
                    irrespective of the thrombosis removal.]</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e975">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e981">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e987">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e993">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e996">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e999">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt;50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1005">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50–100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1011">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1017">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1020">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Proximal Deep Vein Thrombosis of Leg and Inferior Vena Cava Filter if
                    Risk of Bleeding Resolves</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment:</para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1042">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1048">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1054">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1060">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1063">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1066">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1069">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin.]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Pulmonary Embolism</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Clinical Comment: The provider should be advised that the patient is a
                    candidate for intravenous unfractionated heparin, although other options may be
                    preferred; the options for this patient subpopulation cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered: dabigatran (a drug of choice in patients
                    without cancer), rivaroxaban (a drug of choice in patients without cancer),
                    apixaban (a drug of choice in patients without cancer), edoxaban, warfarin
                    (preferred over low molecular weight heparin in patients without cancer),
                    dalteparin (a drug of choice in patients with cancer and in patients with
                    recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or
                    edoxaban), enoxaparin (a drug of choice in patients with cancer and in patients
                    with recurrent venous thromboembolism on warfarin, rivaroxaban, apixaban, or
                    edoxaban), subcutaneous unfractionated heparin, and intravenous heparin. Links
                    to the American College of Chest Physicians VTE treatment guidelines should be
                    provided (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/;
                    http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf). Links to related
                    KNARTs should be created as such KNARTs become available.]</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt;= 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1091">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1097">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1103">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1109">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1112">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1115">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1118">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>High Clinical Suspicion of Acute Pulmonary Embolism</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt;= 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1140">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1146">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1152">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1158">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1161">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1164">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt; 50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1170">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50–100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1176">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1182">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1185">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Intermediate Clinical Suspicion of Acute Pulmonary Embolism if Results of
                    Diagnostic Tests Expected to Be Delayed &gt;4 Hours</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1207">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1213">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1219">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1225">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1228">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1231">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt; 50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1237">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50–100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1243">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1249">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1252">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Pulmonary Embolism and Inferior Vena Cava Filter if Risk of Bleeding
                    Resolves</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1274">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1280">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1286">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1292">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1295">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1298">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1301">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Asymptomatic Pulmonary Embolism</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The provider should be advised that the patient should be
                    considered for the same anticoagulation therapy irrespective of the absence of
                    symptoms related to the pulmonary embolism.]</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt;= 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1326">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1332">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1338">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1344">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1347">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1350">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1353">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Upper-Extremity Deep Vein Thrombosis that Involves Axillary or More
                    Proximal Veins</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous fondaparinux, </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1375">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1381">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1387">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1393">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1396">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1399">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt; 50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1405">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50–100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1411">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1417">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1420">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Acute Upper-Extremity Deep Vein Thrombosis with Thrombolysis</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous fondaparinux, </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Section Prompt: A patient with Acute Upper-Extremity Deep Vein Thrombosis
                    with Thrombolysis should be considered for the same intensity and duration of
                    anticoagulation therapy irrespective of the thrombolysis.]</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1445">
                        <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily </para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1451">
                        <para>☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1457">
                        <para>☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1463">
                        <para>☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1466">
                        <para>☐ Enoxaparin 1 mg/kg solution subcutaneous every 12 hours</para>
                    </listitem>
                    <listitem xml:id="d0e1469">
                        <para>☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24 hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &lt; 50 kg.]</para>
                <para>[Section Prompt: For patients with body weight &lt; 50 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1475">
                        <para>☐ Fondaparinux 5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight =&gt;50–100 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&gt;50-100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1481">
                        <para>☐ Fondaparinux 7.5 mg solution subcutaneous, daily</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following fondaparinux order should be available for
                    patients with body weight &gt; 100 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;100 kg.]</para>
                <itemizedlist mark="none">
                    <listitem xml:id="d0e1487">
                        <para>☐ Fondaparinux 10 mg solution subcutaneous, daily</para>
                    </listitem>
                    <listitem xml:id="d0e1490">
                        <para>☐ Unfractionated heparin 15,000 U solution subcutaneous every 12
                            hours</para>
                    </listitem>
                </itemizedlist>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Symptomatic Splanchnic Vein Thrombosis</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist>
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <para>☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <para xml:id="d0e1518">2610 Dalteparin 12,500 IU solution subcutaneous, daily</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <para xml:id="d0e1524">☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <para xml:id="d0e1530">☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                <para xml:id="d0e1533">☐ Enoxaparin 1 mg/kg solution subcutaneous every 12
                    hours</para>
                <para xml:id="d0e1536">☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24
                    hours</para>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Symptomatic Hepatic Vein Thrombosis</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Be advised that the patient is a candidate for intravenous
                    unfractionated heparin, although other options may be preferred based on
                    individual patient characteristics, clinical co-conditions or co-morbidities,
                    and patient values and preferences. The medication treatment options for this
                    patient subpopulation include the following, but the options cannot be strictly
                    rank-ordered in terms of a universal preference, and individual patient
                    circumstances must be considered in selecting the optimal treatment: </para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>dalteparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous thromboembolism on warfarin, rivaroxaban,
                            apixaban, or edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>enoxaparin (a drug of choice in patients with cancer and in patients
                            with recurrent venous </para>
                    </listitem>
                    <listitem>
                        <para>thromboembolism on warfarin, rivaroxaban, apixaban, or
                            edoxaban),</para>
                    </listitem>
                    <listitem>
                        <para>subcutaneous unfractionated heparin,</para>
                    </listitem>
                    <listitem>
                        <para>intravenous heparin.</para>
                    </listitem>
                </itemizedlist>
                <para>These are links to the American College of Chest Physicians VTE treatment
                    guidelines: (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/</link>), (Kearon,
                    2012); (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf"
                        >http://journal.chestnet.org/article/S0012-3692(15)00335-9/pdf</link>),
                    (Kearon, 2016).] </para>
                <para> [Technical Note: The following dalteparin order should be available for
                    patients with body weight =&lt; 56 kg.]</para>
                <para>[Section Prompt: For patients with body weight =&lt; 56 kg.]</para>
                <para xml:id="d0e1558">☐ Dalteparin 10,000 IU solution subcutaneous, daily</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;56–68 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;56-68 kg.]</para>
                <para xml:id="d0e1564">☐ Dalteparin 12,500 IU solution subcutaneous, daily</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;68–82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;68-82 kg.]</para>
                <para xml:id="d0e1570">☐ Dalteparin 15,000 IU solution subcutaneous, daily</para>
                <para>[Technical Note: The following dalteparin order should be available for
                    patients with body weight &gt;82 kg.]</para>
                <para>[Section Prompt: For patients with body weight &gt;82 kg.]</para>
                <para xml:id="d0e1576">☐ Dalteparin 18,000 IU solution subcutaneous, daily</para>
                <para xml:id="d0e1579">☐ Enoxaparin 1 mg/kg solution subcutaneous every 12
                    hours</para>
                <para xml:id="d0e1582">☐ Enoxaparin 1.5 mg/kg solution subcutaneous every 24
                    hours</para>
                <para>[Technical Note: The following orders are for use in management of IV
                    heparin]</para>
                <para>[Section Prompt: Orders for Initiation and Maintenance of IV Heparin
                    infusion:] </para>
                <para>[Section Selection Behavior: One or both boxes may be selected] </para>
                <para>☐ Heparin 80 U/kg body weight intravenous solution 1 time bolus now </para>
                <para>☐ Start Heparin 18 U/kg body weight/hour IV continuous infusion. Draw aPTT lab
                    6 hours after initiating heparin infusion, and for any aPTT lab result titrate
                    heparin IV infusion per the following protocol: </para>
                <blockquote>
                    <para>If aPTT &lt; 35 sec, give 80 U/kg heparin bolus, then increase heparin
                        infusion rate by 4 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 35-45 sec, give 40 U/kg heparin bolus, then increase heparin
                        infusion rate by 2 U/kg/h, and draw aPTT lab 6 hours after heparin infusion
                        rate change. </para>
                    <para>If aPTT 46-70 sec, no change in heparin infusion rate. If both the current
                        and the previous aPTT value are &gt;=46 and &lt;=70, then draw the next aPTT
                        lab with the next morning lab draw. Otherwise, draw aPTT lab in 6 hours. </para>
                    <para>If aPTT 71-90 sec, then decrease heparin infusion rate by 2 U/kg/h, and
                        draw aPTT lab 6 hours after heparin infusion rate change. </para>
                    <para>If aPTT &gt; 90 sec, hold the heparin infusion for 1 hour, then decrease
                        heparin infusion rate by 3 U/kg/h, and draw aPTT lab 6 hours after heparin
                        infusion rate change.</para>
                </blockquote>
            </section>
            <section>
                <title>Perioperative Anticoagulation with Mechanical Heart Valve, Atrial
                    Fibrillation or Venous Thromboembolism at High Risk for additional
                    (perioperative)Thromboembolism</title>
                <para>[Technical note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Perioperative patients with Mechanical Heart Valve, Atrial
                    Fibrillation or Venous Thromboembolism at High Risk for additional
                    (perioperative)Thromboembolism should be managed according to the American
                    College of Chest Physicians perioperative anticoagulation management guidelines
                        (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/</link>), (Douketis,
                    2012, Section 2.4).]</para>
            </section>
            <section>
                <title>Perioperative Anticoagulation with Unfractionated Heparin Timing of
                    Pre-surgical Stopping of Unfractionated Heparin</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: Timing of Pre-surgical stoppage of Unfractionated Heparin
                    should be managed according to the American College of Chest Physicians
                    perioperative anticoagulation management guidelines. (<link
                        xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278059/</link>), (Douketis,
                    2012, Section 4.2).]</para>
            </section>
            <section>
                <title>Pregnancy with Antiphospholipid Antibody Syndrome</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: The provider should be advised that pregnant patients with
                    Antiphospholipid Antibody Syndrome should be managed according to the American
                    College of Chest Physicians pregnancy anticoagulation guidelines (<link
                        xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/</link>), (Bates,
                    2012, Section 10.2.3).] </para>
            </section>
            <section>
                <title>Pregnancy with Mechanical Heart Valve</title>
                <para>[Technical Note: This subsection should be available for all patients meeting
                    the conditions for the subsection as specified in the ECA rule Inpatient Heparin
                    Anticoagulation Protocol.]</para>
                <para>[Section Prompt: The provider should be advised that the patient should be
                    managed according to the American College of Chest Physicians pregnancy
                    anticoagulation guidelines. (<link xmlns:xlink="http://www.w3.org/1999/xlink"
                        xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/"
                        >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/</link>), (Bates,
                    2012, Section 12.1.1).]</para>
                <para>[End Medications.]</para>
            </section>
        </section>
        <section xml:id="d0e1622">
            <title>Laboratory Tests</title>
            <para>[Begin Laboratory Tests.]</para>
            <para>[Technical Note: This section should be available for all patients for whom the
                ECA rule Inpatient Heparin Anticoagulation Protocol is triggered.]</para>
            <para xml:id="d0e1628">☐ Complete blood count 1 time now</para>
            <para xml:id="d0e1631">☐ Complete blood count 1 time in the morning</para>
            <para xml:id="d0e1634">☐ Basic metabolic profile 1 time now</para>
            <para xml:id="d0e1637">☐ Basic metabolic profile 1 time in the morning</para>
            <para>[If the following order for activated partial thromboplastin time is placed, the
                provider should be prompted to consider discontinuing the activated partial
                thromboplastin time order after the heparin dose has been stable for 48
                hours.]</para>
            <para xml:id="d0e1643">☐ Activated partial thromboplastin time every 6 hours
                routine</para>
            <para xml:id="d0e1646">☐ International normalized ratio daily 1 time routine</para>
            <para>[End Laboratory Tests.]</para>
            <para>[End Order Set.]</para>
            <para/>
        </section>
    </chapter>
    <bibliography>
        <title>Bibliography/Evidence</title>
        <para>HEPARIN SODIUM- heparin sodium injection, solution. DailyMed website. Revised April
            2016</para>
        <biblioentry>
            <abbrev>Bates, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Bates</surname><firstname>SM</firstname></personname>
                </author>
                <author>
                    <personname><surname>Greer</surname><firstname>IA</firstname></personname>
                </author>
                <author>
                    <personname><surname>Middeldorp</surname><firstname>S</firstname></personname>
                </author>
                <author>
                    <personname><surname>Veenstra</surname><firstname>DL</firstname></personname>
                </author>
                <author>
                    <personname><surname>Prabulos</surname><firstname>A-M</firstname></personname>
                </author>
                <author>
                    <personname><surname>Vandvik</surname><firstname>PO</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy:
                Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
                Chest Physicians Evidence-Based Clinical Practice Guidelines.</citetitle>
            <citetitle pubwork="journal">Chest.</citetitle>
            <pubdate>2012;</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl):</issuenum>
            <pagenums>e691S-e736S</pagenums>
        </biblioentry>
        <biblioentry>
            <citetitle pubwork="webpage">Caprini score: DVT risk assessment. Venous Resource Center
                website.</citetitle>
            <bibliomisc><link xlink:href="http://venousdisease.com/caprini-dvt-risk-assessment/"></link></bibliomisc>
            <pubdate>Accessed August 8, 2017.</pubdate>
        </biblioentry>
        <biblioentry>
            <abbrev>Douketis, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Douketis</surname><firstname>JD</firstname></personname>
                </author>
                <author>
                    <personname><surname>Spyropoulos</surname><firstname>AC</firstname></personname>
                </author>
                <author>
                    <personname><surname>Spencer</surname><firstname>FA, et
                        al.</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Perioperative Management of Antithrombotic Therapy:
                Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
                Chest Physicians Evidence-Based Clinical Practice Guidelines.</citetitle>
            <citetitle pubwork="journal">Chest.</citetitle>
            <pubdate>2012;</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl):</issuenum>
            <pagenums>e326S-e350S</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Falck-Ytter, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Falck-Ytter</surname><firstname>Y</firstname></personname>
                </author>
                <author>
                    <personname><surname>Francis</surname><firstname>CW</firstname></personname>
                </author>
                <author>
                    <personname><surname>Johanson</surname><firstname>NA, et
                        al.</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article"> Prevention of VTE in orthopedic surgery patients:
                Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
                Chest Physicians Evidence-Based Clinical Practice Guidelines.</citetitle>
            <citetitle pubwork="journal">Chest.</citetitle>
            <pubdate>2012;</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl):</issuenum>
            <pagenums>e278S-e325S</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Gould, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Gould</surname><firstname>MK</firstname></personname>
                </author>
                <author>
                    <personname><surname>Garcia</surname><firstname>DA</firstname></personname>
                </author>
                <author>
                    <personname><surname>Wren</surname><firstname>SM, et
                        al.</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Prevention of VTE in nonorthopedic surgical patients:
                Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
                Chest Physicians Evidence-Based Clinical Practice Guidelines.</citetitle>
            <citetitle pubwork="journal">Chest.</citetitle>
            <pubdate>2012 Feb;</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl):</issuenum>
            <pagenums>e227S-e277S.</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Kahn, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Kahn</surname><firstname>SR</firstname></personname>
                </author>
                <author>
                    <personname><surname>Lim</surname><firstname>W</firstname></personname>
                </author>
                <author>
                    <personname><surname>Dunn</surname><firstname>AS, et
                        al.</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Prevention of VTE in nonsurgical patients: Antithrombotic
                Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
                Evidence-Based Clinical Practice Guidelines.</citetitle>
            <citetitle pubwork="journal">Chest.</citetitle>
            <pubdate>2012 Feb;</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl):</issuenum>
            <pagenums>e195S-e226S.</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Kearon, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Kearon</surname><firstname>C</firstname></personname>
                </author>
                <author>
                    <personname><surname>Akl</surname><firstname>EA</firstname></personname>
                </author>
                <author>
                    <personname><surname>Comerota</surname><firstname>AJ, et
                        al.</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Antithrombotic therapy for VTE disease: Antithrombotic
                Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
                Evidence-Based Clinical Practice Guidelines.</citetitle>
            <citetitle pubwork="journal">Chest.</citetitle>
            <pubdate>2012 Feb;</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl):</issuenum>
            <pagenums>e419S-e496S.</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Kearon, 2016</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Kearon</surname><firstname>C</firstname></personname>
                </author>
                <author>
                    <personname><surname>Akl</surname><firstname>EA</firstname></personname>
                </author>
                <author>
                    <personname><surname>Ornelas</surname><firstname>J, et
                        al.</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Antithrombotic therapy for VTE disease: CHEST guideline and
                expert panel report.</citetitle>
            <citetitle pubwork="journal">Chest.</citetitle>
            <pubdate>2016;</pubdate>
            <volumenum>149</volumenum>
            <issuenum>(2 Suppl):</issuenum>
            <pagenums>315-352.</pagenums>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>National Academies of Sciences, Engineering, and Medicine.</orgname>
            </author>
            <pubdate>2015.</pubdate>
            <citetitle pubwork="webpage">Improving Diagnosis in Health Care. Washington, DC: The
                National Academies Press.</citetitle>
            <bibliomisc><link xlink:href="https://doi.org/10.17226/21794"/></bibliomisc>
        </biblioentry>
        <biblioentry>
            <citetitle pubwork="webpage">Padua Prediction Score for Risk of VTE. MDCalc
                website.</citetitle>
            <bibliomisc><link xlink:href="https://www.mdcalc.com/padua-prediction-score-risk-vte"
                /></bibliomisc>
            <pubdate>Accessed August 8, 2017.</pubdate>
        </biblioentry>
        <biblioentry>
            <abbrev>Raschke, 1993</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Raschke</surname><firstname>RA</firstname></personname>
                </author>
                <author>
                    <personname><surname>Reilly</surname><firstname>BM</firstname></personname>
                </author>
                <author>
                    <personname><surname>Guidry</surname><firstname>JR</firstname></personname>
                </author>
                <author>
                    <personname><surname>Fontana</surname><firstname>JR</firstname></personname>
                </author>
                <author>
                    <personname><surname>Srinivas</surname><firstname>S.</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">The weight-based heparin dosing nomogram compared with a
                “standard care” nomogram. A randomized controlled trial.</citetitle>
            <citetitle pubwork="journal">Ann Intern Med.</citetitle>
            <pubdate>1993;</pubdate>
            <volumenum>119</volumenum>
            <issuenum>(9):</issuenum>
            <pagenums>874-881.</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Rogers, 2007</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Rogers</surname><firstname>SO Jr</firstname></personname>
                </author>
                <author>
                    <personname><surname>Kilaru</surname><firstname>RK</firstname></personname>
                </author>
                <author>
                    <personname><surname>Hosokawa</surname><firstname>P</firstname></personname>
                </author>
                <author>
                    <personname><surname>Henderson</surname><firstname>WG</firstname></personname>
                </author>
                <author>
                    <personname><surname>Zinner</surname><firstname>MJ</firstname></personname>
                </author>
                <author>
                    <personname><surname>Khuri</surname><firstname>SF</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Multivariable predictors of postoperative venous
                thromboembolic events after general and vascular surgery: results from the patient
                safety in surgery study.</citetitle>
            <citetitle pubwork="journal">J Am Coll Surg.</citetitle>
            <pubdate>2007;</pubdate>
            <volumenum>204</volumenum>
            <issuenum>(6):</issuenum>
            <pagenums>1211-1221.</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Shehab, 2016</abbrev>
            <authorgroup>
                <author>
                    <personname><surname>Shehab</surname><firstname>N</firstname></personname>
                </author>
                <author>
                    <personname><surname>Lovegrove</surname><firstname>MC</firstname></personname>
                </author>
                <author>
                    <personname><surname>Geller</surname><firstname>AI</firstname></personname>
                </author>
                <author>
                    <personname><surname>Rose</surname><firstname>KO</firstname></personname>
                </author>
                <author>
                    <personname><surname>Weidle</surname><firstname>NJ</firstname></personname>
                </author>
                <author>
                    <personname><surname>Budnitz</surname><firstname>DS</firstname></personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">US Emergency Department Visits for Outpatient Adverse Drug
                Events, 2013-2014.</citetitle>
            <citetitle pubwork="journal">JAMA.</citetitle>
            <pubdate>2016;</pubdate>
            <volumenum>316</volumenum>
            <issuenum>(20)</issuenum>
            <pagenums>2115-2125.</pagenums>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">ARIXTRA- fondaparinux sodium injection, solution [Mylan
                Institutional LLC]. DailyMed website.</citetitle>
            <pubdate>Revised October 2015.</pubdate>
            <bibliomisc><link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3b30c68-cf45-4b46-8ba6-72090f7ba01a"/></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">ASPIRIN 81 MG- aspirin tablet, coated [DOLGENCORP, LLC].
                DailyMed website.</citetitle>
            <pubdate>Revised January 2017.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4064039-2345-4227-b83d-54dc13a838d3"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">ELIQUIS- apixaban tablet, film coated [Cardinal Health].
                DailyMed website.</citetitle>
            <pubdate>Revised March 2017.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">ENOXAPARIN SODIUM- enoxaparin sodium injection [Amphastar
                Pharmaceuticals, Inc.]. DailyMed website.</citetitle>
            <pubdate>Revised June 2017.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab8118dc-aca8-478b-8290-a468cbe36ae1"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">FRAGMIN- dalteparin sodium injection, solution [Pfizer,
                Inc.]. DailyMed website.</citetitle>
            <pubdate>Revised March 2009.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=529711c6-6029-4e50-8ece-c0e59b06ff38"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">FONDAPARINUX SODIUM- fondaparinux sodium injection [Dr.
                Reddy's Laboratories Inc.]]. DailyMed website.</citetitle>
            <pubdate>Revised September 2016.</pubdate>
            <bibliomisc><link
                xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a27f341-f612-de72-8c1f-3fd977905de0"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">HEPARIN SODIUM- heparin sodium injection [Pfizer
                Laboratories Div Pfizer Inc]. DailyMed website.</citetitle>
            <pubdate>Revised August 2016.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56dc3074-f1c5-45a3-b923-f1d14858e06d"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">HEPARIN SODIUM- heparin sodium injection, solution.
                DailyMed website.</citetitle>
            <pubdate>Revised April 2016.</pubdate>
            <bibliomisc><link
                xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efcdb321-832b-4554-8049-dbbb33b48334"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">PRADAXA- dabigatran etexilate mesylate capsule [Boehringer
                Ingelheim Pharmaceuticals Inc.]. DailyMed website.</citetitle>
            <pubdate>Revised July 2017.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">WARFARIN SODIUM- warfarin tablet [Exelan Pharmaceuticals
                Inc.]. DailyMed website.</citetitle>
            <pubdate>Revised May 2016.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0cc4511-e656-4b6d-96cd-e02e76173b9d"
                /></bibliomisc>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine.</orgname>
            </author>
            <citetitle pubwork="webpage">XARELTO- rivaroxaban tablet, film coated [Avera McKennan
                Hospital]. DailyMed website.</citetitle>
            <pubdate>Revised December 2015.</pubdate>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1166231a-b23a-4c86-8cda-45d41b724e57"
                /></bibliomisc>
        </biblioentry>
    </bibliography>



    <appendix xml:id="d0e2383">
        <title>Acronyms</title>
        <informaltable>
            <tgroup cols="2">
                <colspec colname="c1" colwidth="50*"/>
                <colspec colname="c2" colwidth="50*"/>
                <tbody valign="top">
                    <row>
                        <entry><para xml:id="d0e2386"><emphasis role="bold"
                                >Acronyms</emphasis></para></entry>
                        <entry><para><emphasis role="bold">Description</emphasis></para></entry>
                    </row>
                    <row>
                        <entry><para>APLA</para></entry>
                        <entry><para>Antiphospholipid Antibody</para></entry>
                    </row>
                    <row>
                        <entry><para>CCWP</para></entry>
                        <entry><para>Clinical Content White Paper</para></entry>
                    </row>
                    <row>
                        <entry><para>CDS</para></entry>
                        <entry><para>Clinical Decision Support</para></entry>
                    </row>
                    <row>
                        <entry><para>DVT</para></entry>
                        <entry><para>Deep Vein Thrombosis</para></entry>
                    </row>
                    <row>
                        <entry><para>ECA</para></entry>
                        <entry><para>Event Condition Action</para></entry>
                    </row>
                    <row>
                        <entry><para>HL7</para></entry>
                        <entry><para>Health Level 7</para></entry>
                    </row>
                    <row>
                        <entry><para>IV</para></entry>
                        <entry><para>Intravenous</para></entry>
                    </row>
                    <row>
                        <entry><para>IVC</para></entry>
                        <entry><para>Inferior vena cava</para></entry>
                    </row>
                    <row>
                        <entry><para>KBS</para></entry>
                        <entry><para>Knowledge Based Systems</para></entry>
                    </row>
                    <row>
                        <entry><para>KNART</para></entry>
                        <entry><para>Knowledge Artifact</para></entry>
                    </row>
                    <row>
                        <entry><para>LMWH</para></entry>
                        <entry><para>Low-molecular-weight heparin</para></entry>
                    </row>
                    <row>
                        <entry><para>OIIG</para></entry>
                        <entry><para>Office of Informatics and Information Governance</para></entry>
                    </row>
                    <row>
                        <entry><para>PE</para></entry>
                        <entry><para>Pulmonary Embolism</para></entry>
                    </row>
                    <row>
                        <entry><para>SC</para></entry>
                        <entry><para>Subcutaneous</para></entry>
                    </row>
                    <row>
                        <entry><para>SME</para></entry>
                        <entry><para>Subject Matter Expert</para></entry>
                    </row>
                    <row>
                        <entry><para>TO</para></entry>
                        <entry><para>Task Order</para></entry>
                    </row>
                    <row>
                        <entry><para>UFH</para></entry>
                        <entry><para>Unfractionated Heparin</para></entry>
                    </row>
                    <row>
                        <entry><para>VA</para></entry>
                        <entry><para>Department of Veteran Affairs</para></entry>
                    </row>
                    <row>
                        <entry><para>VAMC</para></entry>
                        <entry><para>VA Medical Center</para></entry>
                    </row>
                    <row>
                        <entry><para>VTE</para></entry>
                        <entry><para>Venous Thromboembolism</para></entry>
                    </row>
                </tbody>
            </tgroup>
        </informaltable>
    </appendix>
</book>
